Theratechnologies Inc. (TH.TO)

3.0300 +0.0200 (+0.66%) As of 11:54AM EDT. Market open.

Theratechnologies Inc.

2015 Peel Street
11th Floor
Montreal, QC H3A 1T8
Canada

https://www.theratech.com

Sector(s): Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Full Time Employees: 87

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Paul Lévesque	Pres, CEO & Director	1.24M	N/A	1964
Mr. Philippe Dubuc M.B.A., MBA	Sr. VP & CFO	393.59k	N/A	1967
Dr. Christian Marsolais Ph.D.	Sr. VP & Chief Medical Officer	383.71k	N/A	1963
Mr. John Leasure	Global Commercial Officer	353.81k	N/A	1965
Ms. Elif McDonald	Sr. Director of Investor Relations	N/A	N/A	N/A
Mr. Jocelyn Lafond L.L.M., LL.B.	Gen. Counsel & Corp. Sec.	N/A	N/A	1968
Mr. Denis Boucher B.A., L.L.B.	VP of Communications & Corp. Affairs	N/A	N/A	1966
Hon. Andre Dupras	VP of HR	N/A	N/A	1964

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

Corporate Governance

Theratechnologies Inc.’s ISS Governance QualityScore as of June 1, 2022 is 7. The pillar scores are Audit: 9; Board: 6; Shareholder Rights: 9; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.